1. Home
  2. UNB vs VTVT Comparison

UNB vs VTVT Comparison

Compare UNB & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Union Bankshares Inc.

UNB

Union Bankshares Inc.

N/A

Current Price

$23.62

Market Cap

107.6M

Sector

Finance

ML Signal

N/A

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

N/A

Current Price

$35.10

Market Cap

143.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UNB
VTVT
Founded
1891
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
107.6M
143.7M
IPO Year
1999
2015

Fundamental Metrics

Financial Performance
Metric
UNB
VTVT
Price
$23.62
$35.10
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$55.25
AVG Volume (30 Days)
10.2K
31.3K
Earning Date
04-20-2026
06-17-2026
Dividend Yield
6.12%
N/A
EPS Growth
N/A
N/A
EPS
1.82
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.91
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.65
$14.00
52 Week High
$34.85
$44.00

Technical Indicators

Market Signals
Indicator
UNB
VTVT
Relative Strength Index (RSI) 44.31 48.38
Support Level $21.90 $33.62
Resistance Level $25.15 $42.71
Average True Range (ATR) 0.68 3.16
MACD -0.06 -0.19
Stochastic Oscillator 25.10 26.48

Price Performance

Historical Comparison
UNB
VTVT

About UNB Union Bankshares Inc.

Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.

Share on Social Networks: